dc.contributor.author | Pender, A | |
dc.contributor.author | Davis, EJ | |
dc.contributor.author | Chauhan, D | |
dc.contributor.author | Messiou, C | |
dc.contributor.author | Al-Muderis, O | |
dc.contributor.author | Thway, K | |
dc.contributor.author | Fisher, C | |
dc.contributor.author | Zaidi, S | |
dc.contributor.author | Miah, A | |
dc.contributor.author | Judson, I | |
dc.contributor.author | van der Graaf, W | |
dc.contributor.author | Keedy, VL | |
dc.contributor.author | Benson, C | |
dc.contributor.author | Jones, RL | |
dc.date.accessioned | 2018-11-02T11:23:34Z | |
dc.date.issued | 2018-08-20 | |
dc.identifier.citation | Medical oncology (Northwood, London, England), 2018, 35 (10), pp. 131 - ? | |
dc.identifier.issn | 1357-0560 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/2907 | |
dc.identifier.eissn | 1559-131X | |
dc.identifier.doi | 10.1007/s12032-018-1193-5 | |
dc.description.abstract | The outcome for patients with unresectable or metastatic soft tissue sarcoma remains poor with few treatment options. Synovial sarcoma is a rare type of sarcoma, predominantly affecting adolescents and young adults. Following failure of first-line anthracycline-based chemotherapy, several salvage options are available. We reviewed the safety and efficacy of gemcitabine/docetaxel chemotherapy in two tertiary oncology centres. We identified patients treated with gemcitabine/docetaxel between 2004 and 2016 in a UK and a US oncology centre using retrospective pharmacy and medical records. Treatment response, toxicity and outcome data were collected. Twenty one patients were treated with gemcitabine/docetaxel, the majority as a second- or third-line treatment for metastatic disease. The response rate was 5% with a median progression-free survival of 2 months (95% CI 1.3-3.7). Toxicities reported were as expected for this chemotherapy combination. Treatment was not discontinued due to toxicity. Gemcitabine/docetaxel chemotherapy shows little efficacy in synovial sarcoma and should not be offered to this patient group outside a clinical trial context. | |
dc.format | Electronic | |
dc.format.extent | 131 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | HUMANA PRESS INC | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Humans | |
dc.subject | Sarcoma, Synovial | |
dc.subject | Deoxycytidine | |
dc.subject | Antineoplastic Agents | |
dc.subject | Antimetabolites, Antineoplastic | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject | Treatment Outcome | |
dc.subject | Palliative Care | |
dc.subject | Retrospective Studies | |
dc.subject | Adult | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | Male | |
dc.subject | Young Adult | |
dc.title | Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2018-08-12 | |
rioxxterms.versionofrecord | 10.1007/s12032-018-1193-5 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2018-08-20 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Medical oncology (Northwood, London, England) | |
pubs.issue | 10 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Lung Cancer Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Lung Cancer Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 35 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Clinical and Translational Sarcoma | |
icr.researchteam | Sarcoma Clinical Trials (R Jones) | |
icr.researchteam | Lung Cancer Group | |
icr.researchteam | Targeted Therapy | |
dc.contributor.icrauthor | Pender, Alexandra | |